REGULATORY

• Chuikyo Green-Lights Basic Plans on “Optimal Use Guidelines,” Notification Letters
  October 6, 2016

• Chuikyo OKs Application of Huge-Seller Re-Pricing to Opdivo; Payers Loath to Use Ono Sales Outlook for Calculation
  October 6, 2016

• 2nd Round of Sakigake Invitations Gets Underway
  October 5, 2016

• MOF Pushes for Overhaul of Drug Pricing System, Says It Can’t Address Pricy Meds
  October 5, 2016

• Kaketsuken Faces Another Penalty over Encephalitis Vaccine Manufacturing
  October 5, 2016

• MHLW, PMDA Set Up “Preparatory Offices” to Plan Future Support System for Startups
  October 5, 2016

• MHLW Orders Nagoya Univ. to Probe Corrections Made to Diovan Paper
  October 4, 2016

• Bayer Launches Recall of Hemophilia Med Kogenate over Potency Loss
  October 4, 2016

• Drug Discovery Support Network to Announce Withdrawn Research Themes; Companies Will Be Able to Use This as “Negative Data”
  October 4, 2016

• MHLW Says It Will Compile “Optimal Use Guidelines” for Keytruda Too
  October 3, 2016

• Japan’s FY2014 Healthcare Spending Renews Record at 40.8 Trillion Yen
  September 30, 2016

• MID-NET Working Group Kicks Off Discussions on Access Fees
  September 30, 2016

• MHLW OKs Keytruda, Triple Hypertension Combo Micatrio and Other Drugs
  September 29, 2016

• Novartis’ BRAF and MEK Inhibitors Get Orphan Status for NSCLC
  September 29, 2016

• Sales of Sovaldi, Harvoni Peaked Out: MHLW
  September 29, 2016

• Drug Costs Biggest Driver of Healthcare Spending Surge: Chuikyo JMA Rep
  September 29, 2016

• Clinical Research Bill Set to Sail through Extra Diet with Opposition Backing
  September 27, 2016

• Japan Inks Memorandums of Cooperation on Pharmacopoeias with US, Europe, China
  September 27, 2016

• Lawmaker Group Calls for Launch of Int’l Center for Regenerative Medicine
  September 27, 2016

• MHLW to Launch 2nd Round of Sakigake Invitations in Early October
  September 26, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 270
• 271
• 272
• 273
• 274
• 275
• 276
• 277
• 278
• …
• Next ›
• 最終 »